<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>Thessaloniki: Judging Session</title>
        <link>https://video.igem.org/videos/watch/034d285b-f1d8-4786-b1f8-4ee934795b1a</link>
        <description>AETh3R is a novel peptide-PROTAC (PROteolysis TArgeting Chimera)-based strategy for the treatment and management of Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer, challenged by treatment resistance and relapse. Our project targets two key oncogenic drivers: mutant KRAS, which promotes uncontrolled cell proliferation, and MDM2, a negative regulator of the tumor suppressor p53. We aim to degrade both proteins simultaneously, suppressing oncogenic signaling while restoring p53-mediated tumor suppression and apoptosis. This approach employs two heterobifunctional peptide-PROTACs, each comprising a target-binding peptide, a linker, and a von Hippel–Lindau (VHL) E3 ubiquitin ligase-recruiting ligand, triggering target ubiquitination and proteasomal degradation. A targeted lipid nanoparticle delivery system with an optimized, DOTAP-containing formulation favors lung biodistribution, while incorporated anti-Integrin αvβ6 antibody fragments enhance tumor cell-specific uptake. Through computational modeling and experimental validation, AETh3R aims to improve therapeutic targeting and offer a promising, less resistance-prone alternative to conventional inhibition-based therapies.</description>
        <lastBuildDate>Sat, 21 Nov 2026 11:32:15 GMT</lastBuildDate>
        <docs>https://validator.w3.org/feed/docs/rss2.html</docs>
        <generator>PeerTube - https://video.igem.org</generator>
        <image>
            <title>Thessaloniki: Judging Session</title>
            <url>https://video.igem.org/client/assets/images/icons/icon-1500x1500.png</url>
            <link>https://video.igem.org/videos/watch/034d285b-f1d8-4786-b1f8-4ee934795b1a</link>
        </image>
        <copyright>All rights reserved, unless otherwise specified in the terms specified at https://video.igem.org/about and potential licenses granted by each content's rightholder.</copyright>
        <atom:link href="https://video.igem.org/feeds/video-comments.xml?videoId=034d285b-f1d8-4786-b1f8-4ee934795b1a" rel="self" type="application/rss+xml"/>
    </channel>
</rss>